Albinterferon alfa-2b

Drug Profile

Albinterferon alfa-2b

Alternative Names: ABF 656; Albuferon; Albuferon-α; Albumin-interferon alfa; Albumin/interferon-alpha fusion protein - Human Genome Sciences/Novartis; Interferon-alpha/albumin fusion protein - Human Genome Sciences/Novartis; Joulferon; Zalbin

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Human Genome Sciences
  • Developer Human Genome Sciences; Novartis
  • Class Albumins; Antineoplastics; Antivirals; Interferons; Recombinant fusion proteins
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hepatitis B; Hepatitis C

Most Recent Events

  • 03 Aug 2012 Human Genome Sciences has been acquired by GlaxoSmithKline
  • 06 Oct 2010 Discontinued - Phase-I for Hepatitis C in Japan (SC)
  • 06 Oct 2010 Discontinued - Phase-I/II for Hepatitis B in Asia (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top